TrialCancer medicine2023

A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia.

Aref Al-Kali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.